May 19, 2017 / 3:28 PM / 3 months ago

BRIEF-Nordic Nanovector wins approval for continued evaluation of Betalutin dose

May 19 (Reuters) - Nordic Nanovector Asa

* Safety review committee approves continued evaluation of 20 mbq/kg

* the Safety Review Committee (SRC) for the ongoing LYMRIT 37-01 clinical trial of Betalutin in non-Hodgkin's Lymphoma (NHL) has reviewed safety data from the study and approved continued clinical evaluation of 20 MBq/kg Betalutin administered after pre-dosing with 100 mg/m2 lilotomab

* "Recommendation from the SRC represents another important milestone for the development of Betalutin, in line with our strategy and established timelines" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below